InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
InspireMD (Nasdaq: NSPR) will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. The company will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss results and recent highlights.
A live audio webcast and archived recording will be available via the company Investors page, and participants are encouraged to register at least 15 minutes before the call.
Positive
- None.
Negative
- None.
News Market Reaction – NSPR
In the Mar 9 session, NSPR gained 0.61%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 20 | Inducement grant | Neutral | +1.3% | Announcement of 36,118 restricted shares for a new non-executive employee. |
| Jan 12 | Clinical trial data | Positive | -5.8% | Publication of C-GUARDIANS pivotal trial in JACC showing low adverse events. |
| Nov 24 | External study results | Positive | +1.6% | CREST-2 data highlighting benefits of carotid artery stenting supporting CGuard platform. |
| Nov 21 | Inducement grants | Neutral | +13.5% | Grants of 122,054 restricted shares to eight new non-executive employees. |
| Nov 19 | Conference participation | Neutral | -11.5% | Participation announcement for the Piper Sandler 37th Annual Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced mixed reactions, with both sharp gains and declines on generally constructive operational and clinical updates, indicating somewhat inconsistent trading around news.
Over the last several months, InspireMD issued news on clinical validation, employee inducement grants, and conference participation. Notable events included the C-GUARDIANS pivotal trial JACC publication with low adverse event rates on Jan 12, 2026 and positive carotid stenting data from CREST-2 on Nov 24, 2025. Inducement grant announcements on Nov 21, 2025 and Jan 20, 2026 led to varied price moves. Against this backdrop, today’s simple scheduling of Q4 and FY 2025 results fits a pattern of frequent operational disclosures without a consistent price reaction direction.
Key Terms
carotid stent medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.
A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD’s corporate website at https://investors.inspiremd.com. Interested participants are encouraged to register more than 15 minutes before the start of the call.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR.
We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Investor Contact:
Webb Campbell
Gilmartin Group LLC
Webb@gilmartinir.com
investor-relations@inspiremd.com
